THE FIRST batch of Covid-19 inactivated vaccines produced by Sinopharm’s Wuhan institute was produced and made ready for mass use on Sunday after it was granted conditional market approval on Thursday. The institute said it has the capacity to produce 100 million doses per year.
The institute’s biosafety workshop passed a review from national drug regulators, it said on Sunday.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.